HMSA-06 for COVID-19
c19early.org
COVID-19 Treatment Clinical Evidence
COVID-19 involves the interplay of 400+ viral and host proteins and factors, providing many therapeutic targets.
c19early analyzes 6,000+ studies for 210+ treatments—over 17 million hours of research.
Only three high-profit early treatments are approved in the US.
In reality, many treatments reduce risk,
with 25 low-cost treatments approved across 163 countries.
-
Naso/
oropharyngeal treatment Effective Treatment directly to the primary source of initial infection. -
Healthy lifestyles Protective Exercise, sunlight, a healthy diet, and good sleep all reduce risk.
-
Immune support Effective Vitamins A, C, D, and zinc show reduced risk, as with other viruses.
-
Thermotherapy Effective Methods for increasing internal body temperature, enhancing immune system function.
-
Systemic agents Effective Many systemic agents reduce risk, and may be required when infection progresses.
-
High-profit systemic agents Conditional Effective, but with greater access and cost barriers.
-
Monoclonal antibodies Limited Utility Effective but rarely used—high cost, variant dependence, IV/SC admin.
-
Acetaminophen Harmful Increased risk of severe outcomes and mortality.
-
Remdesivir Harmful Increased mortality with longer followup. Increased kidney and liver injury, cardiac disorders.
HMSA-06 may be beneficial for
COVID-19 according to the study below.
COVID-19 involves the interplay of 400+ viral and host proteins and factors providing many therapeutic targets.
Scientists have proposed 11,000+ potential treatments.
c19early.org analyzes
210+ treatments.
We have not reviewed HMSA-06 in detail.
, A Heparan Sulfate Mimetic RAFT Copolymer Inhibits SARS‐CoV‐2 Infection and Ameliorates Viral‐Induced Inflammation, Advanced Science, doi:10.1002/advs.202411737
AbstractThe high transmissibility and mutation ability of coronaviruses enable them to easily escape existing immune protection and also pose a challenge to existing antiviral drugs. Moreover, drugs only targeting viruses cannot always attenuate the “cytokine storm”. Herein, a synthetic heparan sulfate (HS) mimetic, HMSA‐06 is reported, that exhibited antiviral activities against both the SARS‐CoV‐2 prototype and Omicron strains by targeting viral entry and replication. Of particular note, HMSA‐06 demonstrated more potent anti‐SARS‐CoV‐2 effects than PG545 and Roneparstat. SARS‐CoV‐2 is reported to hijack autophagy to facilitate its replication, therefore boosting autophagy can attenuate SARS‐CoV‐2 infection. It is revealed that HMSA‐06, but not a similar HS mimetic that failed to inhibit SARS‐CoV‐2, can upregulate cellular autophagy flux. In addition, HMSA‐06 was found to robustly block the NLRP3‐mediated inflammatory reaction in SARS‐CoV‐2 infected THP‐1 derived macrophages as evidenced by a reduction in inflammasome formation and the subsequent decreased secretion of mature caspase‐1 and IL‐1β. The HMSA‐06's inflammation inhibitory function is further confirmed using a LPS/ATP‐stimulated THP‐1 macrophage model. Altogether, this study has identified a promising HS mimetic to combat SARS‐CoV‐2‐associated diseases by inhibiting viral infection and attenuating viral‐induced inflammatory reaction, providing insights into the development of novel anti‐coronavirus drugs in the future.